View Older Stories View More Recent Stories

Aug 2, 2022 07:00AM SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference
Aug 2, 2022 07:00AM SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference
Jul 15, 2022 06:31AM SpringWorks Therapeutics Inc. (SWTX) Appoints Carlos Alban to its Board
Jul 15, 2022 06:30AM SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors
Jul 15, 2022 06:30AM SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors
Jun 10, 2022 06:31AM SpringWorks Therapeutics Inc. (SWTX) to Present Progress Across the Company’s Targeted Oncology Portfolio at Virtual R&D Day
Jun 10, 2022 06:30AM SpringWorks Therapeutics to Present Progress Across the Company’s Targeted Oncology Portfolio at Virtual R&D Day
Jun 10, 2022 06:30AM SpringWorks Therapeutics to Present Progress Across the Company’s Targeted Oncology Portfolio at Virtual R&D Day
Jun 9, 2022 07:00AM SpringWorks Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
Jun 9, 2022 07:00AM SpringWorks Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
May 27, 2022 07:26AM SpringWorks (SWTX) Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting (earlier)
May 26, 2022 05:15PM SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting
May 26, 2022 05:15PM SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting
May 24, 2022 06:30AM SpringWorks Therapeutics Inc. (SWTX) Reports Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial
May 24, 2022 06:30AM SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors
May 24, 2022 06:30AM SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors
May 16, 2022 08:30AM SpringWorks Therapeutics to Host Virtual R&D Day on June 10, 2022
May 16, 2022 08:30AM SpringWorks Therapeutics to Host Virtual R&D Day on June 10, 2022
May 5, 2022 06:30AM SpringWorks Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 5, 2022 06:30AM SpringWorks Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
Apr 19, 2022 06:31AM SpringWorks Therapeutics Inc. (SWTX) Enters Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458
Apr 19, 2022 06:30AM SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multip
Apr 19, 2022 06:30AM SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multip
Feb 24, 2022 06:30AM SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights
Feb 24, 2022 06:30AM SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights
Feb 1, 2022 06:30AM SpringWorks Therapeutics to Present at Upcoming Investor Conferences
Feb 1, 2022 06:30AM SpringWorks Therapeutics to Present at Upcoming Investor Conferences
Jan 4, 2022 06:30AM SpringWorks Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Jan 4, 2022 06:30AM SpringWorks Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 10, 2021 06:30AM SpringWorks Therapeutics Inc. (SWTX) Announces Clinical Collaboration with AbbVie (ABBV) to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with R/R Multiple Myeloma
Dec 10, 2021 06:30AM SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma
Dec 10, 2021 06:30AM SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma
Dec 6, 2021 06:30AM SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b/2 Trial Evaluating Nirogacestat in Combination with Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple My
Dec 6, 2021 06:30AM SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b/2 Trial Evaluating Nirogacestat in Combination with Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple My
Nov 29, 2021 06:30AM SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas
Nov 29, 2021 06:30AM SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas
Nov 23, 2021 06:30AM SpringWorks Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference
Nov 23, 2021 06:30AM SpringWorks Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference
Nov 4, 2021 06:30AM SpringWorks Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights
Nov 4, 2021 06:30AM SpringWorks Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights
Oct 27, 2021 06:39AM SpringWorks (SWTX) Announces Initiation of Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with B
Oct 27, 2021 06:30AM SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combi
Oct 27, 2021 06:30AM SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combi
Oct 20, 2021 06:45AM SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics
Oct 20, 2021 06:45AM SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics
Oct 20, 2021 06:33AM SpringWorks Therapeutics (SWTX) to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors
Oct 20, 2021 06:30AM SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors
Oct 20, 2021 06:30AM SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors
Sep 7, 2021 06:30AM SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 7, 2021 06:30AM SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
View More Recent Stories View Older Stories